Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for...

Descripción completa

Detalles Bibliográficos
Autor principal: Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/
https://www.ncbi.nlm.nih.gov/pubmed/30249170
http://dx.doi.org/10.1177/1753466618801167
_version_ 1783358054199197696
author Hida, Toyoaki
author_facet Hida, Toyoaki
author_sort Hida, Toyoaki
collection PubMed
description Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab’s efficacy and safety in the treatment of NSCLC patients in Japan.
format Online
Article
Text
id pubmed-6156204
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61562042018-09-27 Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety Hida, Toyoaki Ther Adv Respir Dis Review Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab’s efficacy and safety in the treatment of NSCLC patients in Japan. SAGE Publications 2018-09-25 /pmc/articles/PMC6156204/ /pubmed/30249170 http://dx.doi.org/10.1177/1753466618801167 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Hida, Toyoaki
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title_full Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title_fullStr Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title_full_unstemmed Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title_short Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
title_sort nivolumab for the treatment of japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/
https://www.ncbi.nlm.nih.gov/pubmed/30249170
http://dx.doi.org/10.1177/1753466618801167
work_keys_str_mv AT hidatoyoaki nivolumabforthetreatmentofjapanesepatientswithadvancedmetastaticnonsmallcelllungcancerareviewofclinicaltrialevidenceforefficacyandsafety

Ejemplares similares